Clinical Parameters for Determining Hematologic Toxicity Prior to Radioimmunotherapy

Abstract

New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.

1 . A method of predicting the severity of hematologic toxicity which would result from administration of a radiolabled antibody to a cancer patient deterring or decreasing such hematological toxicity, comprising: 
 (a) measuring the degree of bone marrow involvement in a baseline biopsy; and    (b) administering a therapeutically effective amount of non-labeled, depleting antibody if said baseline bone marrow involvement is higher than 5% such that said bone marrow involvement is decreased to less than 5%.    
   
   
       2 - 52 . (canceled)